Randomized comparative study between short duration (4 hour) vs. 24 hour post-partum magnesium sulphate therapy in severe preeclampsia

Latika Sahu, Preeti Yadav, Anjali Tempe


Background: Objective: To assess the safety and efficacy of shorter duration of magnesium sulphate therapy given till 4 hours after delivery as compared to the standard duration of 24 hours postpartum therapy, given to prevent eclampsia in patients with severe preeclampsia.  

Methods: A prospective randomized controlled study of magnesium sulphate therapy in women with severe preeclampsia was conducted with 50 patients each in control and study group. The control group received 24 hours of postpartum magnesium sulphate therapy and the study group received for 4 hours or one intramuscular dose in postpartum period. Chi square and unpaired “t” test were used for statistical analysis of data; a probability value of <0.05 was considered statistically significant.

Results: There was no statistically significant difference in demographic data, disease severity, maternal and perinatal outcome. The need for IV anti-hypertensive postpartum was significantly higher in study group (12% vs. 0%, P=0.03). No patient developed eclampsia or required reinitiation of therapy. At the end of therapy serum magnesium levels were significantly lower in the study group.  

Conclusions: In patients with severe preeclampsia shorter duration (4 hours or one dose) of postpartum magnesium sulphate therapy, is as effective as the standard 24 hours of postpartum therapy. 


Preeclampsia, Postpartum, Magnesium sulphate, Short duration therapy

Full Text:



Duley L, Matar HE, Almerie MQ, Hall DR. Alternative magnesium sulphate regimens for women with preeclampsia and eclampsia. Cochrane Database Syst Rev. 2010;8:CD007388.

Cunningham, Leveno, Rouse, Hauth, Bloom, Spong. Pregnancy hypertension. Cunningham, Leveno, Rouse, Hauth, Bloom, Spong, eds. William’s Obstetrics. 23rd ed. New York USA: McGraw-Hill; 2010: 706-757.

WHO. Maternal mortality in 2005. In: WWHO, eds. Estimates developed by WHO, UNICEF, UNIFPA and the World Bank. Geneva: World Health Organization; 2007.

Steegers EA, von Dadelszen P, Duvekot JJ, Pijnenborg R. Preeclampsia. Lancet. 2010;376:631-44.

Singhal SR, Deepika, Anshu, Nanda S. Maternal and perinatal outcome in severe preeclampsia and eclampsia. J SAFOG. 2009 Sept-Dec;1(3):25-8.

Simon J, Gray A, Duley L; Magpie Trial Collaborative Group. Cost effectiveness of prophylactic magnesium sulphate for 9996 women with preeclampsia from 33 countries: economic evaluation of the Magpie trial. BJOG. 2006;113:144-51.

Fontenot MT, Lewis DF, Fredrick JB, Wang Y, Deframo EA. A prospective randomized trial of magnesium sulphate in severe preeclampsia: use of dieresis as a clinical parameter to determine the duration of postpartum therapy. Am J Obstet Gynecol. 2005;192:1788-94.

World Health Organization. Who recommendations for prevention and treatment of preeclampsia and eclampsia, 2011. Available at: Accessed 4 February 2012.

Darngawn L, Jose R, Regi A, Bansal R, Jeyaseelan L. A shortened postpartum magnesium sulphate prophylaxis regime in preeclamptic women at low risk of eclampsia. Int J Gynecol Obstet. 2012;116(3):237-9.

Ehrenberg HM, Mercer BM. Abbreviated postpartum magnesium sulphate therapy for women with mild preeclampsia: a randomized controlled trial. Obstet Gynecol. 2006;108(4):833-8.